Jeffrey B. Stavenhagen

Valby, 2500, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Therapeutic targeting of fibrin-microglia interactions ameliorates Alzheimer's disease-related hyperexcitability and brain network dysfunction.

Therapeutic targeting of fibrin-microglia interactions ameliorates Alzheimer's disease-related hyperexcitability and brain network dysfunction.

Journal: bioRxiv : the preprint server for biology

Published: May 18, 2026

Development of a humanized anti-fibrin monoclonal antibody for the treatment of neuroinflammatory and retinal diseases.

Development of a humanized anti-fibrin monoclonal antibody for the treatment of neuroinflammatory and retinal diseases.

Journal: Journal of neuroinflammation

Published: August 18, 2025

Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies.

Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies.

Journal: NPJ Parkinson's disease

Published: May 31, 2024

Fibrin-Targeting Immunotherapy for Dementia.

Fibrin-Targeting Immunotherapy for Dementia.

Journal: The journal of prevention of Alzheimer's disease

Published: October 24, 2023

Longitudinal Imaging of the Skull Base Synchondroses Demonstrate Prevention of a Premature Ossification After Recifercept Treatment in Mouse Model of Achondroplasia.

Longitudinal Imaging of the Skull Base Synchondroses Demonstrate Prevention of a Premature Ossification After Recifercept Treatment in Mouse Model of Achondroplasia.

Journal: JBMR plus

Published: November 17, 2020

In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.

In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.

Journal: PloS one

Published: October 02, 2020

Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life.

Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life.

Journal: Nature neuroscience

Published: February 11, 2020

Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau.

Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau.

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: November 03, 2018

Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcγ-receptor binding and functional lysosomes.

Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcγ-receptor binding and functional lysosomes.

Journal: Scientific reports

Published: September 27, 2018

Development of a Cell-Based Assay to Assess Binding of the proNGF Prodomain to Sortilin.

Development of a Cell-Based Assay to Assess Binding of the proNGF Prodomain to Sortilin.

Journal: Cellular and molecular neurobiology

Published: July 07, 2017

Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration.

Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration.

Journal: Nature immunology

Published: June 17, 2017

Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies.

Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies.

Journal: Acta neuropathologica

Published: June 05, 2015

Showing 1-12 of 14

Last Updated: 09/26/2026